Menu Search
Equities

Ekso Bionics Holdings Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0IFR:LSE

Ekso Bionics Holdings Inc

Actions
  • Price (USD)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta0.7960
Data delayed at least 20 minutes, as of May 30 2025.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves people with physical disabilities or impairments in both physical rehabilitation and mobility. It operates as one segment with two markets: Enterprise Health and Personal Health. Its products include EksoNR, which is a wearable robotic exoskeleton designed for a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower limb-powered exoskeleton; Ekso Indego Personal is a lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. It enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate, stand and walk again. Additionally, the devices assist people with a variety of upper extremity disabilities and enable industrial employees to perform challenging repetitive tasks for extended periods.

  • Revenue in USD (TTM)14.75m
  • Net income in USD-10.66m
  • Incorporated2012
  • Employees61.00
  • Location
    Ekso Bionics Holdings Inc101 GLACIER POINT, SUITE ASAN RAFAEL 94901United StatesUSA
  • Phone+1 (510) 984-1761
  • Fax+1 (702) 866-2689
  • Websitehttps://eksobionics.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.